LUMICEF Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving LUMICEF Growth

1. Strong Mechanism with Differentiated IL-17 Receptor Targeting

LUMICEF(R) is a fully human anti-IL-17 receptor A monoclonal antibody, blocking multiple IL-17 cytokines (IL-17A, IL-17F, IL-17A/F, IL-17C), unlike agents targeting only IL-17A.

• This broader inhibition translates into robust and rapid clinical efficacy in inflammatory diseases like psoriasis.
• Clinical studies and real-world data highlight rapid onset and sustained response, which is a key differentiator vs. other biologics.

Growth implication: Differentiated efficacy profile supports continued physician adoption in biologic-experienced patients.

2. Expanding Indication Base (Lifecycle Management)

LUMICEF has steadily expanded beyond initial psoriasis approval:

• 2016: Approved for multiple psoriasis indications in Japan
• 2020: Added ankylosing spondylitis and non-radiographic axial spondyloarthritis
• 2023: Approved for palmoplantar pustulosis (PPP) (first IL-17 pathway inhibitor for this indication)
• Ongoing: Development in systemic sclerosis (orphan designation)

3. Favorable Clinical Outcomes & Real-World Evidence

Clinical trials and real-world data show:

• Achievement of primary endpoints in Phase 3 PPP trial with confirmed efficacy and safety
• Demonstrated long-term safety and improvement in patient-reported outcomes (PROs)

4. Patient-Friendly Administration Driving Uptake

Recent innovation includes:

• Introduction of pre-filled auto-injector pen (2025) for easier self-administration
• Earlier availability of self-injection option since 2017

Growth implication:

• Improves patient adherence and convenience
• Expands use in outpatient/self-care settings
• Enhances competitiveness vs. IV biologics

5. First-in-Class Position in Certain Indications

• LUMICEF is the first IL-17 pathway inhibitor approved for PPP
• It remains the only anti-IL-17 receptor (IL-17RA) antibody in its class

Growth implication:

• Strong positioning in orphan/rare dermatology segments
• Limited direct competition in certain niches

LUMICEF Recent Developments

• Kyowa Kirin does not publicly break out LUMICEF-specific global sales consistently in press releases.
• However, continued new approvals (2023), device launch (2025), and lifecycle expansion strongly indicate sustained mid-term growth trajectory, particularly in Japan and specialty dermatology segments.

"LUMICEF Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of LUMICEF for approved indication like Ankylosing spondylitis, Axial spondyloarthritis, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Pustular psoriasis in the 7MM. A detailed picture of LUMICEF's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the LUMICEF for approved indications. The LUMICEF market report provides insights about LUMICEF's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current LUMICEF performance, future market assessments inclusive of the LUMICEF market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of LUMICEF sales forecasts, along with factors driving its market.

LUMICEF Drug Summary

LUMICEF (Brodalumab) is a fully human monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It works by selectively binding to the interleukin-17 receptor A (IL-17RA), thereby inhibiting the activity of multiple IL-17 cytokines (including IL-17A, IL-17F, and others) that play a central role in the inflammatory cascade underlying psoriasis. By blocking this receptor, LUMICEF effectively reduces keratinocyte proliferation and inflammation, leading to significant improvements in skin clearance, as demonstrated in clinical trials where a substantial proportion of patients achieved PASI 75, PASI 90, and even complete skin clearance (PASI 100). Administered via subcutaneous injection, LUMICEF has shown rapid onset of action and sustained efficacy; however, its use is associated with warnings regarding potential risk of suicidal ideation and behavior, as well as increased susceptibility to infections, necessitating careful patient selection and monitoring. The report provides LUMICEF's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the LUMICEF Market Report

The report provides insights into:

• A comprehensive product overview including the LUMICEF MoA, description, dosage and administration, research and development activities in approved indication like Ankylosing spondylitis, Axial spondyloarthritis, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Pustular psoriasis.
• Elaborated details on LUMICEF regulatory milestones and other development activities have been provided in LUMICEF market report.
• The report also highlights LUMICEF's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The LUMICEF market report also covers the patents information, generic entry and impact on cost cut.
• The LUMICEF market report contains current and forecasted LUMICEF sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The LUMICEF market report also features the SWOT analysis with analyst views for LUMICEF in approved indications.

Methodology:

The LUMICEF market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUMICEF Analytical Perspective by DelveInsight

• In-depth LUMICEF Market Assessment

This LUMICEF sales market forecast report provides a detailed market assessment of LUMICEF for approved indication like Ankylosing spondylitis, Axial spondyloarthritis, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Pustular psoriasis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted LUMICEF sales data uptil 2034.

• LUMICEF Clinical Assessment

The LUMICEF market report provides the clinical trials information of LUMICEF for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

LUMICEF Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

LUMICEF Market Potential & Revenue Forecast

• Projected market size for the LUMICEF and its key indications
• Estimated LUMICEF sales potential (LUMICEF peak sales forecasts)
• LUMICEF Pricing strategies and reimbursement landscape

LUMICEF Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• LUMICEF Market positioning compared to existing treatments
• LUMICEF Strengths & weaknesses relative to competitors

LUMICEF Regulatory & Commercial Milestones

• LUMICEF Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

LUMICEF Clinical Differentiation

• LUMICEF Efficacy & safety advantages over existing drugs
• LUMICEF Unique selling points

LUMICEF Market Report Highlights

• In the coming years, the LUMICEF market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The LUMICEF companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LUMICEF's dominance.
• Other emerging products for Ankylosing spondylitis, Axial spondyloarthritis, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Pustular psoriasis are expected to give tough market competition to LUMICEF and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LUMICEF in approved indications.
• Analyse LUMICEF cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted LUMICEF sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of LUMICEF in approved indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of LUMICEF? How strong is LUMICEF's clinical and commercial performance?
• What is LUMICEF's clinical trial status in each individual indications such as Ankylosing spondylitis, Axial spondyloarthritis, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Pustular psoriasis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUMICEF Manufacturers?
• What are the key designations that have been granted to LUMICEF for approved indications? How are they going to impact LUMICEF's penetration in various geographies?
• What is the current and forecasted LUMICEF market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of LUMICEF in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LUMICEF for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is LUMICEF? What is the duration of therapy and what are the geographical variations in cost per patient?